PTCH1 and melanoma: Interestingly, we observed that the presence of the BRAFV600E inhibitor, vemurafenib, strongly inhibited the accumulation of doxorubicin in melanoma cells, and in silico docking studies suggested that doxorubicin and vemurafenib bind to Ptch1 at the cholesterol binding site (Figure 7).